Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| CD47 Magrolimab discontinued | >90% | Surface expression on blasts | Wikipedia |
| CD33 | 85-90% | Blast surface expression | Wikipedia |
| CD123 Universal in BPDCN | 70-80% | Blasts and leukaemic stem cells | Wikipedia |
| CD38 | 60-80% | Blast expression, variable intensity | Wikipedia |
| CD70 | 30-50% | Blasts and leukaemic stem cells | Wikipedia |
| CD7 CD7+ AML carries a worse prognosis | 30% | Flow cytometry, CD7 on leukaemic blasts (approximately 30% of AML patients) | doi.org |
| NPM1 mutation ~50-60% of cytogenetically normal AML | 30% | mutation | |
| FLT3 | 25-30% | FLT3-ITD or TKD | cBioPortal (TCGA) |
| Menin KMT2A rearrangement ~5-10% | 25-30% | NPM1 mutation | cBioPortal (TCGA) |
| DNA methyltransferase 3A (DNMT3A) 33.7% in intermediate-risk cytogenetics and absent in favourable-risk disease; R882 the commonest site | 22.1% | DNMT3A mutation, exon sequencing of 281 de novo AML cases (62 mutated) | doi.org |
| IDH1 / IDH2 | 15-20% | IDH1 or IDH2 mutation | cBioPortal (TCGA) |
| TP53 Higher in therapy-related AML | 8-10% | TP53 mutation | cBioPortal (TCGA) |
| KMT2A (MLL) rearrangement Higher in therapy-related AML | 5-10% | rearrangement | |
| BCL-2 | n/a | Dependency, not a prevalence threshold | Wikipedia |
| Retinoic acid receptor alpha (RARA) PML::RARA is present in nearly all cases of acute promyelocytic leukaemia | about 10% | PML::RARA fusion (acute promyelocytic leukaemia subtype) | doi.org |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
7 cell lines, 2 mouse models and 3 repositories are listed for this cancer. See them →